Your session is about to expire
← Back to Search
Nicotine Replacement Therapy
Oral Nicotine Pouches for Tobacco Use Disorder
Phase 1
Recruiting
Led By Tory Spindle, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Self-report at least a one year history of regular smoking
Exhaled breath CO greater than or equal to 10ppm and urine cotinine greater than 100 ng/ml at screening
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6.5 hours
Awards & highlights
No Placebo-Only Group
Summary
This trial studies how healthy adult smokers respond to tobacco-free oral nicotine pouches. The pouches come in various flavors and strengths, and the study measures how the body absorbs and reacts to the nicotine, including effects on withdrawal symptoms and vital signs. Tobacco-free oral nicotine pouch products have emerged as a potential reduced risk product compared with cigarettes and other tobacco products.
Who is the study for?
This trial is for healthy adult smokers who smoke daily, have a mild tobacco use disorder, and haven't used other tobacco products or nicotine pouches recently. They must be over 21 years old with normal vital signs and no recent drug use (except THC). Pregnant women, those in another trial within the last month, or using certain medications are excluded.
What is being tested?
The study tests 'tobacco-free' oral nicotine pouches of different flavors and doses against regular cigarettes to see how they affect the body and cravings. Participants will try each product under controlled conditions first, then freely for two hours in a double-blind setup.
What are the potential side effects?
Possible side effects may include typical nicotine-related symptoms such as increased heart rate, nausea, headache, dizziness, dry mouth or throat irritation from the pouches. Smoking cigarettes carries well-known risks like lung damage and cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been smoking regularly for at least one year.
Select...
My breath and urine tests show high levels of nicotine.
Select...
I am 21 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6.5 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6.5 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Pharmacokinetics of nicotine as assessed by the AUC
Pharmacokinetics of nicotine as assessed by the Cmax
Subjective ratings of "Like Drug Effect" as assessed by the Drug Effect Questionnaire
+4 moreSecondary study objectives
Negative and aversive effects as assessed by the Drug Effect Questionnaire
Perceived strength of effects as assessed by the Drug Effect Questionnaire
Pharmacokinetics of nicotine as assessed by the Tmax
+4 moreSide effects data
From 2014 Phase 4 trial • 127 Patients • NCT0140024365%
Any nonserious adverse event
22%
Itchiness at Patch Site
16%
Nausea
8%
Redness at patch site
5%
Headache
5%
Decreased appetite
2%
Lucid dreams
2%
Hot or sweating
2%
Lightheadedness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Nicotine Patch
Placebo Patch
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
7Treatment groups
Experimental Treatment
Active Control
Group I: Original/Tobacco Flavored Pouch (low nicotine dose)Experimental Treatment1 Intervention
participants will use a tobacco flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Group II: Original/Tobacco Flavored Pouch (high nicotine dose)Experimental Treatment1 Intervention
participants will use a tobacco flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Group III: Mint/Menthol Flavored Pouch (low nicotine dose)Experimental Treatment1 Intervention
participants will use a mint/menthol flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Group IV: Mint/Menthol Flavored Pouch (high nicotine dose)Experimental Treatment1 Intervention
participants will use a mint/menthol flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Group V: Fruit Flavored Pouch (low nicotine dose)Experimental Treatment1 Intervention
participants will use a fruit flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Group VI: Fruit Flavored Pouch (high nicotine dose)Experimental Treatment1 Intervention
participants will use a fruit flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Group VII: Own brand cigarettesActive Control1 Intervention
participants will smoke participants' own brand of cigarettes under both controlled (experimenter-directed) and ad libitum use conditions
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Nicotine replacement therapies (NRT) work by delivering nicotine to the body without the harmful chemicals found in tobacco smoke. This helps to reduce withdrawal symptoms and cravings associated with quitting smoking.
Oral nicotine pouches, similar to other NRTs, deliver nicotine through the oral mucosa, providing a controlled dose that can help manage addiction. This method is particularly beneficial as it mimics the rapid nicotine delivery of smoking, aiding in the transition away from cigarettes.
For patients, understanding these mechanisms is crucial as it highlights the effectiveness of NRTs in reducing dependence on tobacco, thereby lowering the risk of smoking-related diseases.
Effectiveness of dentist's intervention in smoking cessation: A review.Interventions for tobacco cessation in the dental setting.A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.
Effectiveness of dentist's intervention in smoking cessation: A review.Interventions for tobacco cessation in the dental setting.A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Johns Hopkins UniversityLead Sponsor
2,323 Previous Clinical Trials
14,874,244 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,582 Previous Clinical Trials
3,326,984 Total Patients Enrolled
Tory Spindle, PhDPrincipal InvestigatorJohns Hopkins University
5 Previous Clinical Trials
328 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have not used new types of nicotine pouches before, according to your own report.I am not taking any medications or supplements that could affect my safety in the trial.I have been smoking regularly for at least one year.My breath and urine tests show high levels of nicotine.I am 21 years old or older.You have not used any other tobacco products, such as chewing tobacco or e-cigarettes, for at least 30 days.You have a problem with using tobacco, even if it's not severe.You smoke cigarettes every day and have reported this yourself.
Research Study Groups:
This trial has the following groups:- Group 1: Fruit Flavored Pouch (low nicotine dose)
- Group 2: Fruit Flavored Pouch (high nicotine dose)
- Group 3: Own brand cigarettes
- Group 4: Original/Tobacco Flavored Pouch (low nicotine dose)
- Group 5: Original/Tobacco Flavored Pouch (high nicotine dose)
- Group 6: Mint/Menthol Flavored Pouch (low nicotine dose)
- Group 7: Mint/Menthol Flavored Pouch (high nicotine dose)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Drug Effects Patient Testimony for trial: Trial Name: NCT05335915 — Phase 1
Share this study with friends
Copy Link
Messenger